YahooOctober 1, 2026 at 8:55 AM NY26 Days Ago
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
